Celcuity Inc

CELCNASDAQ · USD
79.99USD-4.11 (-4.89%)
119

Celcuity Inc (CELC) Options Open Interest

CELC options open interest is 14,052 contracts. The 2-week average daily volume is 745 contracts across the chain.

Read more

Monitoring CELC open interest helps you see where real money is positioned on Celcuity Inc's options and which strikes are attracting the most commitment from traders. Celcuity Inc's open interest reflects the total number of outstanding contracts that have not been closed or exercised, making it a powerful gauge of liquidity, conviction, and potential support and resistance zones. Use our scanner to monitor CELC options open interest in real time and find the strikes that matter.

Open interest is distinct from volume: volume counts how many contracts are traded in a session, while open interest counts how many remain open at the end of the day. Rising CELC options open interest alongside rising volume suggests new positions are being built, while falling open interest signals positions are being closed. Heavy open interest at specific strikes often acts as a magnet near expiration and can hint at where dealers and large traders expect Celcuity Inc to settle.

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer.

The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Pin risk into expiration, dealer positioning, liquidity checks for large orders — all of it starts with knowing where CELC open interest is concentrated. Our scanner maps Celcuity Inc's open interest across every strike and expiry, flags unusual buildups, and lets you drill into the contracts that institutional money is actually holding. Trade Celcuity Inc's options open interest as the signal it is, not as an afterthought.

2026-10-16
Calls
115.000.750.7586%+0.0950862
85.003.206.104.6558%+0.5078422
90.001.503.202.3553%+0.3374202
100.000.151.000.5852%+0.1120111
95.000.901.951.4356%+0.221554
Puts
70.000.751.451.1071%-0.1321820
80.002.203.502.8556%-0.3308677
75.000.652.851.7563%-0.2101266
65.000.301.250.7882%-0.0879121
100.0014.6018.1016.3555%-0.8728121

As of September 22, 2026

Follow the money

Track CELC open interest across every strike and expiration, identify where conviction is building, and trade with the positioning data on your side.

Start your 14-day free trial